Emulsion-based adjuvants for influenza vaccines. (Q30375985)

21 June 2017

1 reference

title

Emulsion-based adjuvants for influenza vaccines. (English)

1 reference

21 June 2017

Frederick R Vogel

1

1 reference

21 June 2017

Catherine Caillet

series ordinal

2

1 reference

21 June 2017

Inca C Kusters

series ordinal

3

1 reference

21 June 2017

Jean Haensler

series ordinal

4

1 reference

21 June 2017

1 April 2009

1 reference

Expert Review of Vaccines

21 June 2017

10

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

21 June 2017

8

1 reference

21 June 2017

4

1 reference

21 June 2017

483-492

1 reference

The effect of age on the B-cell repertoire

21 June 2017

1 reference

21 January 2018

1 reference

An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine

21 January 2018

1 reference

Developing vaccines against pandemic influenza

21 January 2018

1 reference

Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.

21 January 2018

1 reference

QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immmunization in humans

21 January 2018

1 reference

Prepandemic influenza vaccine H5N1 (split virion, inactivated, adjuvanted) [Prepandrix]: a review of its use as an active immunization against influenza A subtype H5N1 virus

21 January 2018

1 reference

Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS).

21 January 2018

1 reference

Translating innate immunity into immunological memory: implications for vaccine development

21 January 2018

1 reference

Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling.

21 January 2018

1 reference

Ab and T cell epitopes of influenza A virus, knowledge and opportunities

21 January 2018

1 reference

Protective Effect of Vaccination Against Induced Influenza A

21 January 2018

1 reference

Origin and evolution of the 1918 "Spanish" influenza virus hemagglutinin gene

21 January 2018

1 reference

Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant.

21 January 2018

1 reference

The use of adjuvants in studies on influenza immunization. I. Measurements in monkeys of the dimensions of antigenicity of virus-mineral oil emulsions

21 January 2018

1 reference

Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines

21 January 2018

1 reference

Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59.

21 January 2018

1 reference

Distribution of adjuvant MF59 and antigen gD2 after intramuscular injection in mice

21 January 2018

1 reference

The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells

21 January 2018

1 reference

Molecular and cellular signatures of human vaccine adjuvants.

21 January 2018

1 reference

Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly

21 January 2018

1 reference

Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects

21 January 2018

1 reference

Response of influenza vaccines against heterovariant influenza virus strains in adults with chronic diseases.

21 January 2018

1 reference

Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses

21 January 2018

1 reference

Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

21 January 2018

1 reference

Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population

21 January 2018

1 reference

Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy.

21 January 2018

1 reference

Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults

21 January 2018

1 reference

MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection.

21 January 2018

1 reference

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

21 January 2018

1 reference

Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine

21 January 2018

1 reference

Vaccination of macaques with adjuvanted formalin-inactivated influenza A virus (H5N1) vaccines: protection against H5N1 challenge without disease enhancement

21 January 2018

1 reference

An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.

21 January 2018

1 reference

Vaccines with the MF59 adjuvant do not stimulate antibody responses against squalene

21 January 2018

1 reference

21 January 2018

Safety of MF59 adjuvant

1 reference

Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial.

21 January 2018

1 reference

Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERV.09.5

1 reference

21 June 2017

1 reference